S. Landonio

A. d’Arminio Monforte, S. Lazzaroni, M. Valsecchi, 2020, Liver international : official journal of the International Association for the Study of the Liver.

Comparison of the Pharmacokinetics of Raltegravir Given at 2 Doses of 400 mg by Swallowing Versus One Dose of 800 mg by Chewing in Healthy Volunteers: A Randomized, Open-Label, 2-Period, Single-Dose, Crossover Phase 1 Study

E. Clementi, D. Cattaneo, A. Riva, 2015, Therapeutic drug monitoring.

Comparison of the In Vivo Pharmacokinetics and In Vitro Dissolution of Raltegravir in HIV Patients Receiving the Drug by Swallowing or by Chewing

E. Clementi, D. Cattaneo, A. Gazzaniga, 2012, Antimicrobial Agents and Chemotherapy.

Limited Sampling Strategies for the Estimation of Raltegravir Daily Exposure in HIV‐Infected Patients

E. Clementi, D. Cattaneo, D. Ripamonti, 2012, Journal of clinical pharmacology.

Inter- and intra-patient variability of raltegravir pharmacokinetics in HIV-1-infected subjects.

E. Clementi, D. Cattaneo, M. Galli, 2012, The Journal of antimicrobial chemotherapy.

Osteonecrosis in protease inhibitor-treated patients.

P. Bonfanti, T. Quirino, S. Landonio, 2001, Orthopedics.

Multiclass HCV resistance to direct‐acting antiviral failure in real‐life patients advocates for tailored second‐line therapies

F. Ceccherini‐Silberstein, V. Vullo, N. Caporaso, 2017, Liver international : official journal of the International Association for the Study of the Liver.

Low Body Weight in Females Is a Risk Factor for Increased Tenofovir Exposure and Drug-Related Adverse Events

E. Clementi, D. Cattaneo, A. Riva, 2013, PloS one.

Four years data of raltegravir-based salvage therapy in HIV-1-infected, treatment-experienced patients: the SALIR-E Study.

M. Meschiari, S. Lo Caputo, E. Ricci, 2014, International journal of antimicrobial agents.

Resistance analysis and treatment outcomes in hepatitis C virus genotype 3‐infected patients within the Italian network VIRONET‐C

F. Baldanti, F. Ceccherini‐Silberstein, V. Vullo, 2021, Liver international : official journal of the International Association for the Study of the Liver.

HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels.

A. Gasbarrini, F. Ceccherini‐Silberstein, V. Vullo, 2016, The Journal of antimicrobial chemotherapy.

Real-life effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients with previous daa failure.

A. Alberti, P. Lampertico, P. Pozzoni, 2019, Journal of hepatology.

Hepatitis C virus RNA levels at week-2 of telaprevir/boceprevir administration are predictive of virological outcome.

F. Ceccherini‐Silberstein, M. Andreoni, S. Babudieri, 2015, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Predictive factors of lopinavir/ritonavir discontinuation for drug-related toxicity: results from a cohort of 416 multi-experienced HIV-infected individuals.

A. Monforte, P. Cicconi, A. di Biagio, 2005, International journal of antimicrobial agents.

Incidence of adverse reactions in HIV patients treated with protease inhibitors: a cohort study. Coordinamento Italiano Studio Allergia e Infezione da HIV (CISAI) Group.

F. Parazzini, P. Bonfanti, C. Martinelli, 2000 .

Incidence of Adverse Reactions in HIV Patients Treated With Protease Inhibitors: A Cohort Study

F. Parazzini, G. Ghiselli, P. Bonfanti, 2000, Journal of acquired immune deficiency syndromes.

Hypothyroidism in HIV-infected patients who have or have not received HAART.

E. Ricci, E. Chebat, P. Bonfanti, 2004, Clinical Infectious Diseases.

Antiviral Efficacy and Genotypic Resistance Patterns of Combination Therapy with Stavudine/Tenofovir in Highly Active Antiretroviral Therapy Experienced Patients

Stefano Bonora, Stefania Merli, Massimo Andreoni, 2006, Antiviral therapy.

AVT-882 Antinori

A. Antinori, V. Tozzi, M. Andreoni, 2006 .

The effectiveness of desensitization versus rechallenge treatment in HIV-positive patients with previous hypersensitivity to TMP-SMX: a randomized multicentric study. C.I.S.A.I. Group.

F. Parazzini, P. Bonfanti, T. Quirino, 2000, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

Predictive factors of hyperlipidemia in HIV-infected subjects receiving lopinavir/ritonavir.

A. Monforte, P. Cicconi, F. Adorni, 2006, AIDS research and human retroviruses.

Virological Success of Lopinavir/Ritonavir Salvage Regimen is Affected by an Increasing Number of Lopinavir/Ritonavir-Related Mutations

A. Monforte, P. Cicconi, F. Adorni, 2002, Antiviral therapy.

Lopinavir/ritonavir treatment in HIV antiretroviral‐experienced patients: evaluation of risk factors for liver enzyme elevation

P. Duca, A. Castagna, E. Angeli, 2004, HIV medicine.

Prevalence of resistance-associated substitutions and retreatment of patients failing a glecaprevir/pibrentasvir regimen.

F. Ceccherini‐Silberstein, A. Canbay, S. Beckebaum, 2020, The Journal of antimicrobial chemotherapy.

A Boceprevir Failure in a Patient Infected with HCV Genotype 1G: Importance and Limitations of Virus Genotyping Prior to HCV Protease-Inhibitor-Based Therapy

F. Ceccherini‐Silberstein, C. Mirabelli, C. Perno, 2013, Antiviral therapy.

Tenofovir plasma concentrations in post-menopausal versus pre-menopausal HIV-infected women.

D. Cattaneo, A. Riva, M. Galli, 2013, The Journal of antimicrobial chemotherapy.

Risk factors for lipodystrophy in the CISAI cohort.

F. Parazzini, E. Ricci, P. Bonfanti, 2003, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.